{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:34:25Z","timestamp":1784309665911,"version":"3.55.0"},"reference-count":141,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":117,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81901214"],"award-info":[{"award-number":["81901214"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82330040"],"award-info":[{"award-number":["82330040"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82090044"],"award-info":[{"award-number":["82090044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81820108010"],"award-info":[{"award-number":["81820108010"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFC3044800"],"award-info":[{"award-number":["2024YFC3044800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hubei Province Key Research and Development Program","award":["2022BCA008"],"award-info":[{"award-number":["2022BCA008"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Thrombolytic therapy is a cornerstone in managing acute ischaemic stroke, marking significant advancements in treatment. Various generations of thrombolytics play crucial roles in different strategies, including intravenous thrombolysis, bridging therapy and thrombolysis beyond the conventional time window. The continuous development of thrombolytics has brought notable improvements. Compared to first-generation urokinase, second-generation alteplase and third-generation tenecteplase offer significant pharmacological advantages, such as enhanced fibrin specificity and longer half-lives. Tenecteplase demonstrates non-inferiority to alteplase regarding efficacy and safety, with the added benefit of a more convenient administration method. Ongoing trials continue to reveal additional evidence. Furthermore, other thrombolytic agents, including reteplase and non-immunogenic recombinant staphylokinase, are gaining increasing interest in the medical community. This review examines the structural characteristics, pharmacological properties, efficacy and safety profiles of these thrombolytic drugs. It also provides a detailed analysis of the performance of thrombolytic therapy in different acute ischaemic stroke patient subgroups, aiming to trace the evolution of these treatments and compare their effectiveness in acute ischaemic stroke. The goal is to offer a scientific basis for clinical practices and future development of thrombolytic therapies.<\/jats:p>","DOI":"10.1093\/braincomms\/fcaf164","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T18:19:23Z","timestamp":1745864363000},"source":"Crossref","is-referenced-by-count":13,"title":["Thrombolysis for acute ischaemic stroke: development and update"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8695-7721","authenticated-orcid":false,"given":"Jiashuo","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanwei","family":"He","sequence":"additional","affiliation":[{"name":"Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengcai","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1864-0714","authenticated-orcid":false,"given":"Yan","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"issue":"10440","key":"2025050614465562200_fcaf164-B1","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: A systematic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"Ferrari","year":"2024","journal-title":"Lancet"},{"issue":"10446","key":"2025050614465562200_fcaf164-B2","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1016\/S0140-6736(24)00642-1","article-title":"Stroke","volume":"403","author":"Hilkens","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"2025050614465562200_fcaf164-B3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.5853\/jos.2019.02978","article-title":"Beyond the brain: The systemic pathophysiological response to acute ischemic stroke","volume":"22","author":"Balch","year":"2020","journal-title":"J Stroke"},{"issue":"24","key":"2025050614465562200_fcaf164-B4","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","author":"National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group","year":"1995","journal-title":"N Engl J Med"},{"issue":"06","key":"2025050614465562200_fcaf164-B5","first-page":"523","article-title":"Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023","volume":"57","author":"Chinese Society of Neurology, Chinese Stroke Society","year":"2024","journal-title":"Chin J Neurol"},{"issue":"1","key":"2025050614465562200_fcaf164-B6","doi-asserted-by":"crossref","first-page":"I","DOI":"10.1177\/2396987321989865","article-title":"European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke","volume":"6","author":"Berge","year":"2021","journal-title":"Eur Stroke J"},{"issue":"12","key":"2025050614465562200_fcaf164-B7","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"issue":"24","key":"2025050614465562200_fcaf164-B8","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1056\/NEJMoa2400314","article-title":"Reteplase versus alteplase for acute ischemic stroke","volume":"390","author":"Li","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"2025050614465562200_fcaf164-B9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM199607183350301","article-title":"Thrombolytic therapy with streptokinase in acute ischemic stroke","volume":"335","author":"Multicenter Acute Stroke Trial\u2013Europe Study Group","year":"1996","journal-title":"N Engl J Med"},{"issue":"12","key":"2025050614465562200_fcaf164-B10","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jama.1996.03540120039031","article-title":"Streptokinase for acute ischemic stroke with relationship to time of administration: Australian streptokinase (ASK) trial study group","volume":"276","author":"Donnan","year":"1996","journal-title":"JAMA"},{"issue":"8989","key":"2025050614465562200_fcaf164-B11","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S0140-6736(95)92049-8","article-title":"Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke","volume":"346","author":"Multicentre Acute Stroke Trial-Italy (MAST-I) Group","year":"1995","journal-title":"Lancet"},{"issue":"21","key":"2025050614465562200_fcaf164-B12","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.282.21.2003","article-title":"Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in acute cerebral thromboembolism","volume":"282","author":"Furlan","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"2025050614465562200_fcaf164-B13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5853\/jos.2020.03349","article-title":"Development and testing of thrombolytics in stroke","volume":"23","author":"Nikitin","year":"2021","journal-title":"J Stroke"},{"issue":"3","key":"2025050614465562200_fcaf164-B14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.2174\/187152508784871945","article-title":"Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy","volume":"6","author":"Longstaff","year":"2008","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"issue":"6","key":"2025050614465562200_fcaf164-B15","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1016\/S0021-9258(19)81051-7","article-title":"Kinetics of the activation of plasminogen by human tissue plasminogen activator","volume":"257","author":"Hoylaerts","year":"1982","journal-title":"J Biol Chem"},{"issue":"4","key":"2025050614465562200_fcaf164-B16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/21655979.2016.1229718","article-title":"The evolution of recombinant thrombolytics: Current status and future directions","volume":"8","author":"Adivitiya","year":"2017","journal-title":"Bioengineered"},{"issue":"10347","key":"2025050614465562200_fcaf164-B17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(22)01054-6","article-title":"Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): A pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial","volume":"400","author":"Menon","year":"2022","journal-title":"Lancet"},{"issue":"10377","key":"2025050614465562200_fcaf164-B18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(22)02600-9","article-title":"Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): A phase 3, multicentre, open-label, randomised controlled, non-inferiority trial","volume":"401","author":"Wang","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"2025050614465562200_fcaf164-B19","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1474-4422(21)00210-6","article-title":"Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4\u00b75 h after symptom onset in Russia (FRIDA): A randomised, open label, multicentre, parallel-group, non-inferiority trial","volume":"20","author":"Gusev","year":"2021","journal-title":"Lancet Neurol"},{"issue":"11","key":"2025050614465562200_fcaf164-B20","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1073\/pnas.81.11.3557","article-title":"Streptokinase: Cloning, expression, and excretion by Escherichia coli","volume":"81","author":"Malke","year":"1984","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025050614465562200_fcaf164-B21","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.csbj.2019.06.023","article-title":"Structural biology and protein engineering of thrombolytics","volume":"17","author":"Mican","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"issue":"4","key":"2025050614465562200_fcaf164-B22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.biotechadv.2003.09.004","article-title":"Streptokinase\u2014a clinically useful thrombolytic agent","volume":"22","author":"Banerjee","year":"2004","journal-title":"Biotechnol Adv"},{"issue":"2","key":"2025050614465562200_fcaf164-B23","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0021-9258(17)32743-6","article-title":"Activation of human plasminogen by equimolar levels of streptokinase","volume":"252","author":"Bajaj","year":"1977","journal-title":"J Biol Chem"},{"key":"2025050614465562200_fcaf164-B24","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nbt1085-923","article-title":"Cloning and expression of the gene for pro-urokinase in Escherichia coli","volume":"3","author":"Holmes","year":"1985","journal-title":"Bio\/Technology"},{"issue":"Suppl","key":"2025050614465562200_fcaf164-B25","doi-asserted-by":"crossref","first-page":"91s","DOI":"10.1378\/chest.101.4_Supplement.91S","article-title":"Pharmacology of fibrinolysis","volume":"101","author":"Haire","year":"1992","journal-title":"Chest"},{"key":"2025050614465562200_fcaf164-B26","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1021\/bi00148a019","article-title":"Heparin binding to the urokinase Kringle domain","volume":"31","author":"Stephens","year":"1992","journal-title":"Biochemistry"},{"issue":"4","key":"2025050614465562200_fcaf164-B27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2165\/00023210-200317040-00001","article-title":"Clinical potential of intra-arterial thrombolytic therapy in patients with acute ischaemic stroke","volume":"17","author":"Xavier","year":"2003","journal-title":"CNS Drugs"},{"issue":"3","key":"2025050614465562200_fcaf164-B28","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/01.CIR.82.3.1062","article-title":"Molecular biologic modification of plasminogen activators an artful science","volume":"82","author":"Loscalzo","year":"1990","journal-title":"Circulation"},{"issue":"Suppl F","key":"2025050614465562200_fcaf164-B29","doi-asserted-by":"crossref","first-page":"F11","DOI":"10.1093\/eurheartj\/18.suppl_F.11","article-title":"Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator","volume":"18","author":"Smalling","year":"1997","journal-title":"Eur Heart J"},{"issue":"8","key":"2025050614465562200_fcaf164-B30","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00018-019-03005-8","article-title":"The role of endogenous tissue-type plasminogen activator in neuronal survival after ischemic stroke: Friend or foe?","volume":"76","author":"Zhu","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"2025050614465562200_fcaf164-B31","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1073\/pnas.91.9.3670","article-title":"A faster-acting and more potent form of tissue plasminogen activator","volume":"91","author":"Keyt","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2025050614465562200_fcaf164-B32","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood.V78.2.401.401","article-title":"The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: Localization of interaction sites and physiologic relevance","volume":"78","author":"Keijer","year":"1991","journal-title":"Blood"},{"issue":"4","key":"2025050614465562200_fcaf164-B33","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/0268-9499(92)90075-S","article-title":"Primary structure and gene structure of staphylokinase","volume":"6","author":"Collen","year":"1992","journal-title":"Fibrinolysis"},{"issue":"3","key":"2025050614465562200_fcaf164-B34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1023\/A:1018678925512","article-title":"NMR secondary structure of the plasminogen activator protein staphylokinase","volume":"9","author":"Ohlenschl\u00e4ger","year":"1997","journal-title":"J Biomol NMR"},{"issue":"10","key":"2025050614465562200_fcaf164-B35","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1161\/STROKEAHA.107.488551","article-title":"Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: The middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan","volume":"38","author":"Ogawa","year":"2007","journal-title":"Stroke"},{"issue":"1","key":"2025050614465562200_fcaf164-B36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/01.STR.29.1.4","article-title":"PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke","volume":"29","author":"del Zoppo","year":"1998","journal-title":"Stroke"},{"key":"2025050614465562200_fcaf164-B37","doi-asserted-by":"crossref","first-page":"685454","DOI":"10.3389\/fneur.2021.685454","article-title":"Outcomes and treatment complications of intravenous urokinase thrombolysis in acute ischemic stroke in China","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Neurol"},{"issue":"4","key":"2025050614465562200_fcaf164-B38","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1136\/svn-2020-000640","article-title":"Effectiveness of intravenous r-tPA versus UK for acute ischaemic stroke: A nationwide prospective Chinese registry study","volume":"6","author":"Wang","year":"2021","journal-title":"Stroke Vasc Neurol"},{"issue":"9558","key":"2025050614465562200_fcaf164-B39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(07)60154-8","article-title":"Established treatments for acute ischaemic stroke","volume":"369","author":"Khaja","year":"2007","journal-title":"Lancet"},{"issue":"11","key":"2025050614465562200_fcaf164-B40","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1161\/hs1101.098639","article-title":"Thrombolysis for acute ischemic stroke a consensus statement of the 3rd Karolinska Stroke Update, October 30\u201331, 2000","volume":"32","author":"Kaste","year":"2001","journal-title":"Stroke"},{"issue":"21","key":"2025050614465562200_fcaf164-B41","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.282.21.2019","article-title":"Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: A randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke","volume":"282","author":"Clark","year":"1999","journal-title":"JAMA"},{"issue":"4","key":"2025050614465562200_fcaf164-B42","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1474-4422(08)70044-9","article-title":"Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): A placebo-controlled randomised trial","volume":"7","author":"Davis","year":"2008","journal-title":"Lancet Neurol"},{"issue":"13","key":"2025050614465562200_fcaf164-B43","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke","volume":"359","author":"Hacke","year":"2008","journal-title":"N Engl J Med"},{"key":"2025050614465562200_fcaf164-B44","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(10)60491-6","article-title":"Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials","volume":"375","author":"Lees","year":"2010","journal-title":"Lancet"},{"issue":"9834","key":"2025050614465562200_fcaf164-B45","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/S0140-6736(12)60768-5","article-title":"The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): A randomised controlled trial","volume":"379","author":"IST-3 collaborative group","year":"2012","journal-title":"Lancet"},{"issue":"9834","key":"2025050614465562200_fcaf164-B46","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/S0140-6736(12)60738-7","article-title":"Recombinant tissue plasminogen activator for acute ischaemic stroke: An updated systematic review and meta-analysis","volume":"379","author":"Wardlaw","year":"2012","journal-title":"Lancet"},{"issue":"19","key":"2025050614465562200_fcaf164-B47","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJMoa1813046","article-title":"Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke","volume":"380","author":"Ma","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"2025050614465562200_fcaf164-B48","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/STROKEAHA.116.015233","article-title":"Stroke with unknown time of symptom onset: Baseline clinical and magnetic resonance imaging data of the first thousand patients in WAKE-UP (efficacy and safety of MRI-based thrombolysis in wake-up stroke: A randomized, double blind, placebo-controlled trial)","volume":"48","author":"Thomalla","year":"2017","journal-title":"Stroke"},{"issue":"7","key":"2025050614465562200_fcaf164-B49","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa1804355","article-title":"MRI-Guided Thrombolysis for stroke with unknown time of onset","volume":"379","author":"Thomalla","year":"2018","journal-title":"N Engl J Med"},{"issue":"10193","key":"2025050614465562200_fcaf164-B50","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0140-6736(19)31053-0","article-title":"Extending thrombolysis to 4\u00b75\u20139 h and wake-up stroke using perfusion imaging: A systematic review and meta-analysis of individual patient data","volume":"394","author":"Campbell","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"2025050614465562200_fcaf164-B51","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S1474-4422(16)30177-6","article-title":"Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): A randomised controlled trial","volume":"15","author":"Bracard","year":"2016","journal-title":"Lancet Neurol"},{"key":"2025050614465562200_fcaf164-B52","doi-asserted-by":"crossref","first-page":"i1754","DOI":"10.1136\/bmj.i1754","article-title":"Endovascular treatment versus medical care alone for ischaemic stroke: Systematic review and meta-analysis","volume":"353","author":"Rodrigues","year":"2016","journal-title":"BMJ"},{"issue":"21","key":"2025050614465562200_fcaf164-B53","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2001123","article-title":"Endovascular thrombectomy with or without intravenous alteplase in acute stroke","volume":"382","author":"Yang","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"2025050614465562200_fcaf164-B54","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1001\/jama.2020.23522","article-title":"Effect of mechanical thrombectomy without vs with intravenous thrombolysis on functional outcome among patients with acute ischemic stroke: The SKIP randomized clinical trial","volume":"325","author":"Suzuki","year":"2021","journal-title":"JAMA"},{"issue":"20","key":"2025050614465562200_fcaf164-B55","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1056\/NEJMoa2107727","article-title":"A randomized trial of intravenous alteplase before endovascular treatment for stroke","volume":"385","author":"LeCouffe","year":"2021","journal-title":"N Engl J Med"},{"issue":"10346","key":"2025050614465562200_fcaf164-B56","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0140-6736(22)00564-5","article-title":"Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4.5 h of stroke onset: An open-label, blinded-endpoint, randomised non-inferiority trial","volume":"400","author":"Mitchell","year":"2022","journal-title":"Lancet"},{"issue":"10346","key":"2025050614465562200_fcaf164-B57","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(22)00537-2","article-title":"Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: An open-label, blinded-outcome, randomised non-inferiority trial","volume":"400","author":"Fischer","year":"2022","journal-title":"Lancet"},{"issue":"10406","key":"2025050614465562200_fcaf164-B58","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0140-6736(23)01142-X","article-title":"Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke: Individual participant data meta-analysis of six randomised trials","volume":"402","author":"Majoie","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"2025050614465562200_fcaf164-B59","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/svn-2020-000378","article-title":"Chinese stroke association guidelines for clinical management of cerebrovascular disorders: Executive summary and 2019 update of clinical management of ischaemic cerebrovascular diseases","volume":"5","author":"Liu","year":"2020","journal-title":"Stroke Vasc Neurol."},{"issue":"9","key":"2025050614465562200_fcaf164-B60","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/jama.2022.1645","article-title":"Effect of intra-arterial alteplase vs placebo following successful thrombectomy on functional outcomes in patients with large vessel occlusion acute ischemic stroke","volume":"327","author":"Ren\u00fa","year":"2022","journal-title":"JAMA"},{"key":"2025050614465562200_fcaf164-B61","author":"Qureshi","year":"2023"},{"issue":"6","key":"2025050614465562200_fcaf164-B62","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1161\/STROKEAHA.121.037376","article-title":"Presto (Prehospital Stroke Treatment Organization) writing group","volume":"53","author":"Navi","year":"2022","journal-title":"Stroke"},{"issue":"5","key":"2025050614465562200_fcaf164-B63","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1001\/jama.2020.26345","article-title":"Association between dispatch of mobile stroke units and functional outcomes among patients with acute ischemic stroke in Berlin","volume":"325","author":"Ebinger","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"2025050614465562200_fcaf164-B64","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa2103879","article-title":"Prospective, multicenter, controlled trial of mobile stroke units","volume":"385","author":"Grotta","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2025050614465562200_fcaf164-B65","doi-asserted-by":"crossref","first-page":"XXVII","DOI":"10.1177\/23969873221079413","article-title":"European Stroke Organisation (ESO) guidelines on mobile stroke units for prehospital stroke management","volume":"7","author":"Walter","year":"2022","journal-title":"Eur Stroke J"},{"issue":"7","key":"2025050614465562200_fcaf164-B66","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1136\/jnnp.2010.223149","article-title":"Intravenous thrombolysis in acute ischaemic stroke: A systematic review and meta-analysis to aid decision making in patients over 80 years of age","volume":"82","author":"Bhatnagar","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9958","key":"2025050614465562200_fcaf164-B67","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(14)60584-5","article-title":"Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: A meta-analysis of individual patient data from randomised trials","volume":"384","author":"Emberson","year":"2014","journal-title":"Lancet"},{"issue":"15","key":"2025050614465562200_fcaf164-B68","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1212\/WNL.0000000000004499","article-title":"Outcome after stroke thrombolysis in patients &gt;80 years treated within 3 hours vs &gt;3\u20134.5 hours","volume":"89","author":"Ahmed","year":"2017","journal-title":"Neurology"},{"issue":"12","key":"2025050614465562200_fcaf164-B69","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1161\/STROKEAHA.122.039426","article-title":"Intravenous thrombolysis in patients with ischemic stroke aged \u226590 years: A cohort study from the TRISP collaboration","volume":"53","author":"Altersberger","year":"2022","journal-title":"Stroke"},{"issue":"9","key":"2025050614465562200_fcaf164-B70","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/STROKEAHA.117.017808","article-title":"Influence of renal impairment on outcome for thrombolysis-treated acute ischemic stroke","volume":"48","author":"Carr","year":"2017","journal-title":"Stroke"},{"issue":"11","key":"2025050614465562200_fcaf164-B71","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1161\/STROKEAHA.113.002859","article-title":"Severe renal impairment is associated with symptomatic intracerebral hemorrhage after thrombolysis for ischemic stroke","volume":"44","author":"T\u00fct\u00fcnc\u00fc","year":"2013","journal-title":"Stroke"},{"issue":"2","key":"2025050614465562200_fcaf164-B72","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1212\/WNL.0000000000009756","article-title":"Intravenous thrombolysis in patients with chronic kidney disease","volume":"95","author":"Malhotra","year":"2020","journal-title":"Neurology"},{"key":"2025050614465562200_fcaf164-B73","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1212\/01.wnl.0000435550.83200.9e","article-title":"IV thrombolysis and renal function","volume":"81","author":"Gensicke","year":"2013","journal-title":"Neurology"},{"issue":"11","key":"2025050614465562200_fcaf164-B74","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/neurintsurg-2021-018003","article-title":"Influence of renal impairment on clinical outcomes after endovascular recanalization in vertebrobasilar artery occlusions","volume":"14","author":"Xiao","year":"2022","journal-title":"J Neurointerv Surg"},{"issue":"11","key":"2025050614465562200_fcaf164-B75","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1161\/STROKEAHA.122.039086","article-title":"Alteplase for stroke with unknown onset time in chronic kidney disease: A pooled analysis of individual participant data","volume":"53","author":"Miwa","year":"2022","journal-title":"Stroke"},{"issue":"7","key":"2025050614465562200_fcaf164-B76","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1161\/STROKEAHA.112.650838","article-title":"Impact of atrial fibrillation on outcome in thrombolyzed patients with stroke","volume":"43","author":"Frank","year":"2012","journal-title":"Stroke"},{"issue":"3","key":"2025050614465562200_fcaf164-B77","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/STROKEAHA.114.006573","article-title":"Alteplase for acute ischemic stroke","volume":"46","author":"Lindley","year":"2015","journal-title":"Stroke"},{"issue":"12","key":"2025050614465562200_fcaf164-B78","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1007\/s00415-013-7119-4","article-title":"Outcome of patients with atrial fibrillation after intravenous thrombolysis for cerebral ischaemia","volume":"260","author":"Padjen","year":"2013","journal-title":"J Neurol"},{"issue":"10","key":"2025050614465562200_fcaf164-B79","doi-asserted-by":"crossref","first-page":"e3054","DOI":"10.1097\/MD.0000000000003054","article-title":"Atrial fibrillation is associated with poor outcomes in thrombolyzed patients with acute ischemic stroke: A systematic review and meta-analysis","volume":"95","author":"Yue","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2025050614465562200_fcaf164-B80","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1161\/STROKEAHA.119.028127","article-title":"Thrombolysis with alteplase at 0.6 mg\/kg for stroke with unknown time of onset: A randomized controlled trial","volume":"51","author":"Koga","year":"2020","journal-title":"Stroke"},{"issue":"6","key":"2025050614465562200_fcaf164-B81","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamaneurol.2016.0292","article-title":"Risk of symptomatic intracerebral hemorrhage after intravenous thrombolysis in patients with acute ischemic stroke and high cerebral microbleed burden: A meta-analysis","volume":"73","author":"Tsivgoulis","year":"2016","journal-title":"JAMA Neurol"},{"issue":"3","key":"2025050614465562200_fcaf164-B82","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1212\/WNL.0000000000013055","article-title":"Cerebral microbleeds and treatment effect of intravenous thrombolysis in acute stroke: An analysis of the WAKE-UP randomized clinical trial","volume":"98","author":"Schlemm","year":"2022","journal-title":"Neurology"},{"issue":"7","key":"2025050614465562200_fcaf164-B83","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1161\/STROKEAHA.122.040247","article-title":"Intravenous thrombolysis in patients with white matter hyperintensities in the WAKE-UP trial","volume":"54","author":"Frey","year":"2023","journal-title":"Stroke"},{"issue":"2","key":"2025050614465562200_fcaf164-B84","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1161\/STR.0000000000000086","article-title":"Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: A statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"47","author":"Demaerschalk","year":"2016","journal-title":"Stroke"},{"issue":"11","key":"2025050614465562200_fcaf164-B85","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1161\/STROKEAHA.120.030898","article-title":"Reperfusion therapy frequency and outcomes in mild ischemic stroke in the United States","volume":"51","author":"Saber","year":"2020","journal-title":"Stroke"},{"issue":"2","key":"2025050614465562200_fcaf164-B86","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2018.8496","article-title":"Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits: The PRISMS randomized clinical trial","volume":"320","author":"Khatri","year":"2018","journal-title":"JAMA"},{"issue":"24","key":"2025050614465562200_fcaf164-B87","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1001\/jama.2023.7827","article-title":"Dual antiplatelet therapy vs alteplase for patients with minor nondisabling acute ischemic stroke: The ARAMIS randomized clinical trial","volume":"329","author":"Chen","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"2025050614465562200_fcaf164-B88","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1161\/STROKEAHA.124.048248","article-title":"Dual antiplatelet versus alteplase for early neurologic deterioration in minor stroke with versus without large vessel occlusion: Prespecified post hoc analysis of the ARAMIS trial","volume":"55","author":"Cui","year":"2024","journal-title":"Stroke"},{"issue":"4","key":"2025050614465562200_fcaf164-B89","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1161\/STROKEAHA.123.045495","article-title":"Intravenous alteplase versus best medical therapy for patients with minor stroke: A systematic review and meta-analysis","volume":"55","author":"Zhang","year":"2024","journal-title":"Stroke"},{"issue":"3","key":"2025050614465562200_fcaf164-B90","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/23969873241237312","article-title":"Intravenous alteplase in minor nondisabling ischemic stroke: A systematic review and meta-analysis","volume":"9","author":"Alhazzani","year":"2024","journal-title":"Eur Stroke J"},{"issue":"6","key":"2025050614465562200_fcaf164-B91","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/svn-2023-002828","article-title":"Intravenous tenecteplase compared with alteplase for minor ischaemic stroke: A secondary analysis of the AcT randomised clinical trial","volume":"9","author":"Nair","year":"2024","journal-title":"Stroke Vasc Neurol"},{"issue":"6","key":"2025050614465562200_fcaf164-B92","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1161\/STROKEAHA.110.609693","article-title":"The importance of size: Successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length","volume":"42","author":"Riedel","year":"2011","journal-title":"Stroke"},{"issue":"3","key":"2025050614465562200_fcaf164-B93","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jamaneurol.2020.4557","article-title":"Prediction of early neurological deterioration in individuals with minor stroke and large vessel occlusion intended for intravenous thrombolysis alone","volume":"78","author":"Seners","year":"2021","journal-title":"JAMA Neurol"},{"issue":"3","key":"2025050614465562200_fcaf164-B94","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1161\/STROKEAHA.118.023455","article-title":"Thrombus length predicts lack of post-thrombolysis early recanalization in minor stroke with large vessel occlusion","volume":"50","author":"Seners","year":"2019","journal-title":"Stroke"},{"issue":"3","key":"2025050614465562200_fcaf164-B95","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/01.STR.0000154872.73240.e9","article-title":"A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke","volume":"36","author":"Haley","year":"2005","journal-title":"Stroke"},{"issue":"4","key":"2025050614465562200_fcaf164-B96","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1161\/STROKEAHA.109.572040","article-title":"Phase IIB\/III trial of tenecteplase in acute ischemic stroke","volume":"41","author":"Haley","year":"2010","journal-title":"Stroke"},{"issue":"12","key":"2025050614465562200_fcaf164-B97","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa1109842","article-title":"A randomized trial of tenecteplase versus alteplase for acute ischemic stroke","volume":"366","author":"Parsons","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"2025050614465562200_fcaf164-B98","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1161\/STROKEAHA.114.008504","article-title":"Tenecteplase\u2013tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion","volume":"46","author":"Coutts","year":"2015","journal-title":"Stroke"},{"issue":"10444","key":"2025050614465562200_fcaf164-B99","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/S0140-6736(24)00921-8","article-title":"Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): A randomised, open label, phase 3 superiority trial","volume":"403","author":"Coutts","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"2025050614465562200_fcaf164-B100","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1474-4422(17)30253-3","article-title":"Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): A phase 3, randomised, open-label, blinded endpoint trial","volume":"16","author":"Logallo","year":"2017","journal-title":"Lancet Neurol"},{"issue":"6","key":"2025050614465562200_fcaf164-B101","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S1474-4422(22)00124-7","article-title":"Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): A phase 3, randomised, open-label, blinded endpoint, non-inferiority trial","volume":"21","author":"Kvistad","year":"2022","journal-title":"Lancet Neurol"},{"issue":"1","key":"2025050614465562200_fcaf164-B102","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/svn-2021-000978","article-title":"Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): A multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study","volume":"7","author":"Li","year":"2022","journal-title":"Stroke Vasc Neurol"},{"issue":"4","key":"2025050614465562200_fcaf164-B103","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S1474-4422(15)70017-7","article-title":"Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): A phase 2, randomised, open-label, blinded endpoint study","volume":"14","author":"Huang","year":"2015","journal-title":"Lancet Neurol"},{"issue":"11","key":"2025050614465562200_fcaf164-B104","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1474-4422(24)00377-6","article-title":"Tenecteplase versus alteplase for acute stroke within 4.5 h of onset (ATTEST-2): A randomised, parallel group, open-label trial","volume":"23","author":"Muir","year":"2024","journal-title":"Lancet Neurol"},{"issue":"11","key":"2025050614465562200_fcaf164-B105","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1161\/STROKEAHA.123.044267","article-title":"Effect of time to thrombolysis on clinical outcomes in patients with acute ischemic stroke treated with tenecteplase compared to alteplase: Analysis from the AcT randomized controlled trial","volume":"54","author":"Singh","year":"2023","journal-title":"Stroke"},{"key":"2025050614465562200_fcaf164-B106","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2024-003381","article-title":"Tenecteplase thrombolytic therapy for acute ischaemic stroke in China: A real-world, multicentre, retrospective, controlled study","author":"Liu","journal-title":"Stroke Vasc Neurol"},{"issue":"4","key":"2025050614465562200_fcaf164-B107","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/23969873231187436","article-title":"Tenecteplase real-world data: A three phase sequential comparison","volume":"8","author":"Ranta","year":"2023","journal-title":"Eur Stroke J"},{"issue":"9","key":"2025050614465562200_fcaf164-B108","first-page":"666","article-title":"Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018","volume":"51","author":"Chinese Society of Neurology, Chinese Stroke Society","year":"2018","journal-title":"Chin J Neurol"},{"issue":"3","key":"2025050614465562200_fcaf164-B109","doi-asserted-by":"crossref","first-page":"371","DOI":"10.5853\/jos.2023.00668","article-title":"Intravenous tenecteplase for acute ischemic stroke within 4.5\u201324 hours of onset (ROSE-TNK): A phase 2, randomized, multicenter study","volume":"25","author":"Wang","year":"2023","journal-title":"J Stroke"},{"issue":"2","key":"2025050614465562200_fcaf164-B110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1474-4422(22)00484-7","article-title":"Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): A multicentre, open-label, randomised controlled trial","volume":"22","author":"Roaldsen","year":"2023","journal-title":"Lancet Neurol"},{"issue":"8","key":"2025050614465562200_fcaf164-B111","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJMoa2310392","article-title":"Tenecteplase for stroke at 4.5 to 24 hours with perfusion-imaging selection","volume":"390","author":"Albers","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"2025050614465562200_fcaf164-B112","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJMoa2310392","article-title":"Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy","volume":"390","author":"Xiong","year":"2024","journal-title":"N Engl J Med"},{"issue":"17","key":"2025050614465562200_fcaf164-B113","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa1716405","article-title":"Tenecteplase versus alteplase before thrombectomy for ischemic stroke","volume":"378","author":"Campbell","year":"2018","journal-title":"N Engl J Med"},{"issue":"13","key":"2025050614465562200_fcaf164-B114","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jama.2020.1511","article-title":"Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: The EXTEND-IA TNK part 2 randomized clinical trial","volume":"323","author":"Campbell","year":"2020","journal-title":"JAMA"},{"issue":"10","key":"2025050614465562200_fcaf164-B115","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1161\/STROKEAHA.123.042691","article-title":"Early recanalization among patients undergoing bridging therapy with tenecteplase or alteplase","volume":"54","author":"Checkouri","year":"2023","journal-title":"Stroke"},{"issue":"1","key":"2025050614465562200_fcaf164-B116","doi-asserted-by":"crossref","first-page":"e209398","DOI":"10.1212\/WNL.0000000000209398","article-title":"Functional outcome and hemorrhage rates after bridging therapy with tenecteplase or alteplase in patients with large ischemic core","volume":"103","author":"Gerschenfeld","year":"2024","journal-title":"Neurology"},{"issue":"6","key":"2025050614465562200_fcaf164-B117","first-page":"684","article-title":"Chinese guideline for endovascular treatment of acute ischemic stroke 2023","volume":"16","author":"Chinese Stroke Association, Chinese Interventional Neuroradiology Society, Intervention Group of Committee of Stroke Prevention and Control of Chinese Preventive Medicine Association","year":"2023","journal-title":"Chin J Stroke"},{"key":"2025050614465562200_fcaf164-B118","doi-asserted-by":"crossref","first-page":"1155269","DOI":"10.3389\/fneur.2023.1155269","article-title":"Intra-arterial tenecteplase is safe and may improve the first-pass recanalization for acute ischemic stroke with large-artery atherosclerosis: The BRETIS-TNK trial","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Neurol"},{"issue":"6","key":"2025050614465562200_fcaf164-B119","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(22)00171-5","article-title":"Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): A phase 2, randomised, open-label trial","volume":"21","author":"Bivard","year":"2022","journal-title":"Lancet Neurol"},{"issue":"2","key":"2025050614465562200_fcaf164-B120","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/STROKEAHA.123.045193","article-title":"Safety and efficacy of reteplase versus alteplase for acute ischemic stroke: A phase 2 randomized controlled trial","volume":"55","author":"Li","year":"2024","journal-title":"Stroke"},{"key":"2025050614465562200_fcaf164-B121","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/jama.1964.03070050039011","article-title":"Anticoagulants plus streptokinase therapy in progressive stroke","volume":"189","author":"Meyer","year":"1964","journal-title":"JAMA"},{"issue":"4","key":"2025050614465562200_fcaf164-B122","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1254\/jphs.FP0050872","article-title":"Effects of intra-arterial urokinase on a non-human primate thromboembolic stroke model","volume":"100","author":"Susumu","year":"2006","journal-title":"J Pharmacol Sci"},{"issue":"7","key":"2025050614465562200_fcaf164-B123","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1161\/01.STR.0000020713.89227.B7","article-title":"Intra-arterial thrombolysis in 100 patients with acute stroke due to middle cerebral artery occlusion","volume":"33","author":"Arnold","year":"2002","journal-title":"Stroke"},{"key":"2025050614465562200_fcaf164-B124","first-page":"769","article-title":"Intra-arterial reteplase compared to urokinase for thrombolytic recanalization in acute ischemic stroke","volume":"27","author":"Sugg","year":"2006","journal-title":"AJNR Am J Neuroradiol"},{"issue":"3","key":"2025050614465562200_fcaf164-B125","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaneurol.2019.4192","article-title":"Safety and efficacy of intra-arterial urokinase after failed, unsuccessful, or incomplete mechanical thrombectomy in anterior circulation large-vessel occlusion stroke","volume":"77","author":"Kaesmacher","year":"2020","journal-title":"JAMA Neurol"},{"issue":"24","key":"2025050614465562200_fcaf164-B126","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1515510","article-title":"Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke","volume":"374","author":"Anderson","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2025050614465562200_fcaf164-B127","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/STR.0000000000000158","article-title":"2018 guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"49","author":"Powers","year":"2018","journal-title":"Stroke"},{"issue":"5","key":"2025050614465562200_fcaf164-B128","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1161\/STROKEAHA.118.024575","article-title":"Safety and outcome of intravenous thrombolysis in stroke patients on prophylactic doses of low molecular weight heparins at stroke onset","volume":"50","author":"Cooray","year":"2019","journal-title":"Stroke"},{"issue":"4","key":"2025050614465562200_fcaf164-B129","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1177\/23969873241252751","article-title":"Intravenous thrombolysis in patients with recent intake of direct oral anticoagulants: A target trial analysis after the liberalization of institutional guidelines","volume":"9","author":"Bucke","year":"2024","journal-title":"Eur Stroke J"},{"issue":"3","key":"2025050614465562200_fcaf164-B130","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/jamaneurol.2022.4782","article-title":"Intravenous thrombolysis in patients with ischemic stroke and recent ingestion of direct oral anticoagulants","volume":"80","author":"Meinel","year":"2023","journal-title":"JAMA Neurol"},{"issue":"1","key":"2025050614465562200_fcaf164-B131","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jamainternmed.2023.6160","article-title":"Risk of bleeding following non-vitamin K antagonist oral anticoagulant use in patients with acute ischemic stroke treated with alteplase","volume":"184","author":"Tsai","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"8","key":"2025050614465562200_fcaf164-B132","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jama.2022.0948","article-title":"Association of recent use of non-vitamin K antagonist oral anticoagulants with intracranial hemorrhage among patients with acute ischemic stroke treated with alteplase","volume":"327","author":"Kam","year":"2022","journal-title":"JAMA"},{"issue":"7","key":"2025050614465562200_fcaf164-B133","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaneurol.2023.1449","article-title":"Symptomatic intracranial hemorrhage with tenecteplase vs alteplase in patients with acute ischemic stroke","volume":"80","author":"Warach","year":"2023","journal-title":"JAMA Neurol"},{"issue":"3","key":"2025050614465562200_fcaf164-B134","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1161\/STROKEAHA.120.030859","article-title":"Routine use of tenecteplase for thrombolysis in acute ischemic stroke","volume":"52","author":"Zhong","year":"2021","journal-title":"Stroke"},{"issue":"10","key":"2025050614465562200_fcaf164-B135","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.1161\/STROKEAHA.121.035931","article-title":"Switching to tenecteplase for stroke thrombolysis","volume":"52","author":"Mahawish","year":"2021","journal-title":"Stroke"},{"issue":"12","key":"2025050614465562200_fcaf164-B136","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1161\/STROKEAHA.122.038950","article-title":"Prospective observational cohort study of tenecteplase versus alteplase in routine clinical practice","volume":"53","author":"Warach","year":"2022","journal-title":"Stroke"},{"key":"2025050614465562200_fcaf164-B137","doi-asserted-by":"crossref","first-page":"1386386","DOI":"10.3389\/fneur.2024.1386386","article-title":"Real-world data of tenecteplase vs. alteplase in the treatment of acute ischemic stroke: A single-center analysis","volume":"15","author":"Yao","year":"2024","journal-title":"Front Neurol."},{"issue":"3","key":"2025050614465562200_fcaf164-B138","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1177\/23969873231174943","article-title":"Cost-effectiveness of tenecteplase versus alteplase for acute ischemic stroke","volume":"8","author":"Nguyen","year":"2023","journal-title":"Eur Stroke J"},{"issue":"12","key":"2025050614465562200_fcaf164-B139","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1161\/STROKEAHA.120.029666","article-title":"Cost-effectiveness of tenecteplase before thrombectomy for ischemic stroke","volume":"51","author":"Gao","year":"2020","journal-title":"Stroke"},{"issue":"2","key":"2025050614465562200_fcaf164-B140","first-page":"e2178","article-title":"Tenecteplase versus alteplase for the management of acute ischemic stroke in a low-income country-Nepal: Cost, efficacy, and safety","volume":"10","author":"Nepal","year":"2018","journal-title":"Cureus"},{"key":"2025050614465562200_fcaf164-B141","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jocn.2022.09.015","article-title":"Safety and efficacy of low-cost alternative urokinase in acute ischemic stroke: A systematic review and meta-analysis","volume":"106","author":"Kharel","year":"2022","journal-title":"J Clin Neurosci"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcaf164\/63023488\/fcaf164.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/7\/3\/fcaf164\/63023488\/fcaf164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/7\/3\/fcaf164\/63023488\/fcaf164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T18:47:22Z","timestamp":1746557242000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcaf164\/8121321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":141,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcaf164","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"fcaf164"}}